Connect Biopharma
CNTB2.1001.87% ( -0.040 )
Connect Biopharma (CNTB)
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG...
- Open
- 2.150
- High
- 2.200
- Low
- 2.080
- Prev. Close
- 2.140
- Volume
- 189.97K
- Turnover
- 406.15K
- Avg Price
- 2.138
- Bid/Ask Ratio
- --
- Amplitude
- 5.61%
- 52wk High
- 3.820
- Volume Ratio
- 0.61
- Turnover Ratio
- 1.01%
Connect Biopharma Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$7.13239.29%
Forecast & RatingStrong buy
8analysts
- Strong buy87.50%
- Buy12.50%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 13 at 07:22 PM
Connect Biopharma posts investor presentation highlighting rademikibart program in asthma, COPD exacerbations
- rttnews · Jul 9 at 09:55 PM
Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch
- Tip Ranks · Jul 9 at 12:25 PM
Connect Biopharma Holdings (CNTB) Receives a New Rating from Oppenheimer
- benzinga_article · Jul 9 at 09:57 AM
Connect Biopharma shares are trading higher after Oppenheimer initiated its coverage on the stock with a Outperform rating and announced a price target of $8.
- Tip Ranks · Jun 26 at 05:05 AM
Biren Amin Initiates Buy on Rademikibart Developer with Overweight Rating and DCF-Based $7 Price Target on Differentiated Asthma/COPD Opportunity
- Tip Ranks · Jun 25 at 05:56 AM
Buy Rating Reiterated on Connect Biopharma as Analyst Sees Underappreciated Rademikibart Upside; $7 Price Target Maintained
